Serotonin receptor responsivity in schizophrenia.
Kahn
R S
RS
Department of Psychiatry, University Hospital Utrecht, The Netherlands.
Davidson
M
M
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology; D012701:Serotonin / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D010879:Piperazines; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D003024:Clozapine; C015068:1-(3-chlorophenyl)piperazine; D004298:Dopamine